ARC Centre of Excellence for Functional Nanomaterials, The University of Queensland, Brisbane, QLD 4072, Australia.
Biomaterials. 2010 Jul;31(20):5455-62. doi: 10.1016/j.biomaterials.2010.03.050. Epub 2010 Apr 20.
Surgical procedures to remove atherosclerotic lesions and restore blood flow also injure the artery wall, promoting vascular smooth muscle cell (SMC) phenotypic change, migration, proliferation, matrix production and ultimately, restenosis of the artery. Hence identification of effective anti-restenotic strategies is a high priority in cardiovascular research, and SMCs are a key target for intervention. This paper presents the in vitro study of layered double hydroxides (LDHs) as drug delivery system for an anti-restenotic drug (low molecular weight heparin, LMWH). The cytotoxicity tests showed that LDH itself had very limited toxicity at concentrations below 50 microg/mL over 6-day incubation. LDH nanoparticles loaded with LMWH (LMWH-LDHs) were prepared and tested on rat vascular SMCs. When conjugated to LDH particles, LMWH enhanced its ability to inhibit SMC proliferation and migration, with greater than above 60% reduction compared with the control (growth medium) over 3 or 7-day incubation. Cellular uptake studies showed that compared with LMWH alone, LMWH-LDH hybrids were internalized by SMCs more rapidly, and uptake was sustained over a longer time, possibly revealing the mechanisms underlying the enhanced biological function of LMWH-LDH. The results suggest the potential of LMWH-LDH as an efficient anti-restenotic drug for clinical application.
外科手术切除动脉粥样硬化病变并恢复血流也会损伤动脉壁,促进血管平滑肌细胞 (SMC) 的表型改变、迁移、增殖、基质产生,最终导致动脉再狭窄。因此,确定有效的抗再狭窄策略是心血管研究的重中之重,而 SMC 是干预的关键靶点。本文介绍了将层状双氢氧化物 (LDHs) 作为抗再狭窄药物(低分子量肝素,LMWH)的药物递送系统的体外研究。细胞毒性试验表明,在 6 天孵育期内,浓度低于 50μg/mL 的 LDH 本身的毒性非常有限。载有 LMWH 的 LDH 纳米颗粒(LMWH-LDHs)已制备并在大鼠血管平滑肌细胞上进行了测试。当与 LDH 颗粒结合时,LMWH 增强了其抑制 SMC 增殖和迁移的能力,与对照(生长培养基)相比,在 3 或 7 天孵育期内,抑制率超过 60%。细胞摄取研究表明,与单独的 LMWH 相比,LMWH-LDH 杂化物被 SMC 更快地内化,并且摄取持续时间更长,这可能揭示了 LMWH-LDH 增强生物学功能的潜在机制。结果表明,LMWH-LDH 有潜力成为临床应用的高效抗再狭窄药物。